Temozolomide-induced severe myelosuppression: Analysis of clinically associated polymorphisms in two patients

Robert K. Sylvester, Preston Steen, John M. Tate, Minesh Mehta, Ryan J. Petrich, Alexander Berg, Jill Kolesar

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Genotyping of putative determinants of temozolomide (TMZ)-induced life-threatening bone marrow suppression was performed in two patients with glioma treated with adjuvant TMZ and radiation therapy. DNA was extracted from the patients' mononuclear cells and genotyping of O-methylguanine-DNA- methyltransferase (MGMT), multidrug resistance (MDR1; also known as ABCB1), NQO1, and GSTP1 genes and analysis for the epigenetic silencing of specific MGMT gene promoters were carried out to evaluate the possible genetic determinants of increased risk of severe TMZ-induced myelosuppression. Although both patients were heterozygous for all ABCB1 single nucleotide polymorphisms and for rs12917 and rs1803965 in the MGMT gene, patient 1 was heterozygous for rs1695 in GSTP1 and rs2308327 in the MGMT gene. This patient also exhibited GG genotype for the MGMT single nucleotide polymorphisms, rs2308321, which is noteworthy for its 0.7% frequency globally. Epigenetic silencing of MGMT gene was not detected in either patient. Two single nucleotide polymorphisms identified in patient 1 (missense I143V and K178R polymorphisms; rs2308321 and rs2308327, respectively) have recently been shown to correlate with an increased risk of severe TMZ-induced myelosuppression. The polymorphisms identified in patient 2 have not been associated with an increased risk of severe TMZ-induced myelosuppression. Genotyping analyses of larger patient populations administered TMZ are required to validate the genetic determinants of severe TMZ-induced myelosuppression.

Original languageEnglish
Pages (from-to)104-110
Number of pages7
JournalAnti-Cancer Drugs
Volume22
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • O6-methylguanine-DNA- methyltransferase polymorphism
  • epigenetic silencing
  • glioblastoma
  • multidrug resistance gene
  • myelosuppression
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint

Dive into the research topics of 'Temozolomide-induced severe myelosuppression: Analysis of clinically associated polymorphisms in two patients'. Together they form a unique fingerprint.

Cite this